Psilera Unveils Novel, Non-Hallucinogenic Psilocybin Derivative PSIL-006 As Lead Clinical Candidate
PSIL-006 is the first drug candidate from Psilera’s extensive pipeline to progress into advanced safety studies prior to first-in-human clinical trials TAMPA, Fla., May 25, 2023 /PRNewswire/ — Psilera, a biopharmaceutical company developing next-generation mental health treatments for take home use, announces the selection of their lead clinical candidate, PSIL-006. This novel drug with similar … Read more